文献速递肾小球疾病

羟氯喹对IgA肾病蛋白尿影响的随机对照试验

Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2019-03-25

这项双盲随机安慰剂对照2期试验纳入60例已优化RAAS抑制剂治疗但仍有蛋白尿的IgA肾病患者,评估加用羟氯喹6个月的疗效与安全性。结果显示羟氯喹组蛋白尿较基线下降48.4%,显著优于安慰剂组,且无严重不良事件。结论提示羟氯喹可显著降低IgA肾病患者蛋白尿,但需更大规模试验验证。

要点

  • 羟氯喹联合优化RAAS抑制治疗6个月显著降低IgA肾病患者蛋白尿。
  • 6个月时羟氯喹组蛋白尿中位数0.9g/d,显著低于安慰剂组1.9g/d。
  • 研究中两组均未记录到严重不良事件。

核心结论

  • 在优化RAAS抑制剂治疗基础上加用羟氯喹6个月可显著降低IgA肾病患者蛋白尿,且未观察到不良事件证据,但需更大规模治疗试验确认。

研究设计与样本

  • 双盲、随机、安慰剂对照的2期临床试验,纳入60例IgA肾病患者,按1:1随机分配至每日口服羟氯喹组(n=30)或安慰剂组(n=30),治疗6个月。

主要发现

  • 6个月时蛋白尿较基线的百分比变化在羟氯喹组为-48.4%(IQR,-64.2%,-30.5%),安慰剂组为10.0%(IQR,-38.7%,30.6%),组间差异显著(P<0.001)。
  • 6个月时羟氯喹组蛋白尿中位水平为0.9(IQR,0.6,1.0)g/d,显著低于安慰剂组的1.9(IQR,0.9,2.6)g/d(P=0.002)。
  • 研究期间两组均未记录到严重不良事件。

关键数值与推荐

  • 纳入标准:IgA肾病患者,蛋白尿0.75-3.5g/d,估算肾小球滤过率>30mL/min/1.73m2,且正在接受优化RAAS抑制剂治疗。
  • 主要结局为基线与6个月之间蛋白尿的百分比变化。

临床怎么用

  • 对于已优化RAAS抑制剂治疗但仍有持续蛋白尿的IgA肾病患者,加用羟氯喹可能有助于降低蛋白尿。
  • 羟氯喹在此短期试验中耐受性良好,但长期肾脏保护疗效和安全性尚未确定,需更大规模试验证实。

局限性

  • 治疗周期短且缺乏撤药后观察,限制了对长期肾脏保护疗效和安全性的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Despite optimization of renin-angiotensin-aldosterone system (RAAS) inhibition, patients with immunoglobulin A nephropathy (IgAN) and persistent proteinuria remain at risk for kidney failure. We evaluated the efficacy and safety of hydroxychloroquine (HCQ), an immunomodulator, when added to the treatment regimen of patients with IgAN. STUDY DESIGN: Double-blind, randomized, placebo-controlled, phase 2 clinical trial. SETTING & PARTICIPANTS: Participants had IgAN (proteinuria with protein excretion of 0.75-3.5g/d and estimated glomerular filtration rate>30mL/min/1.73m2) and were receiving optimized RAAS inhibitor therapy. INTERVENTIONS: Patients were randomly assigned 1:1 to receive daily oral HCQ or a placebo for 6 months. OUTCOMES: The primary outcome was percentage change in proteinuria between baseline and 6 months. RESULTS: 60 participants (mean estimated glomerular filtration rate, 53.8mL/min/1.73m2; median urine protein excretion, 1.7g/d) were recruited and randomly assigned to receive HCQ (n=30) or placebo (n=30). Percentage change in proteinuria at 6 months was significantly different between the HCQ group and the placebo group (-48.4% [IQR, -64.2%, -30.5%] vs 10.0% [IQR, -38.7%, 30.6%]; P<0.001, respectively). At 6 months, median proteinuria level was significantly lower in the HCQ group than in the placebo group (0.9 [IQR, 0.6, 1.0] g/d vs 1.9 [IQR, 0.9, 2.6] g/d; P=0.002, respectively). No serious adverse events were recorded during the study in either study group. LIMITATIONS: The short treatment period and lack of postwithdrawal observations limit conclusions about long-term renoprotective efficacy and safety. CONCLUSIONS: HCQ in addition to optimized RAAS inhibition significantly reduced proteinuria in patients with IgAN over 6 months without evidence of adverse events. These findings require confirmation in larger treatment trials. FUNDING: This study was supported by grants from a government entity, the Capital of Clinical Characteristics, and the Applied Research Fund. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02942381.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Liu LJ, Yang YZ, Shi SF, et al. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019. PMID: 30922594. doi:10.1053/j.ajkd.2019.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。